Latest news, articles and downloads from Camena Bioscience
5/26/24 | 3 minute read
In recent years, there has been significant interest in using an enzyme called Terminal deoxynucleotidyl transferase (TdT) to produce synthetic DNA. If we're a cutting-edge DNA synthesis company, why aren't we using TdT?
Read more
Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, today announced it has closed a $10m Series A financing round, led by Mercia.
Divina Newman and Nika Pierre joined the Camena team for 8 weeks over the summer. It was initially 6 but such was their committment to learning and contribution to ongoing projects, we asked them to stay. We're immensely proud of their accomplishments and the programme enriched the whole team. We asked Divina and Nika to share their experiences.
Following its $10 million Series A financing1 earlier in the year, the appointment forms part of the Company’s growth plans to expand commercialisation of its pioneering DNA synthesis platform, gSynth™.
Camena Bioscience signs up for two exciting initiatives, 10,000 Black Interns and In2Science.
Last week marked a significant milestone for our team as we successfully delivered the longest DNA construct we've ever created—a staggering 6.5 kilobases (kb).
